PLYMOUTH MEETING, Pa., April 14, 2022
The National Comprehensive Cancer Network—a non-profit based in the United States—is providing free patient-tailored cancer treatment guides to help Ukrainians with cancer get the best possible care, available online at NCCN.org/Ukraine.
PLYMOUTH MEETING, Pa., April 14, 2022 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading U.S. cancer centers—joins the global plea for peace in Ukraine and recognizes the profound impact to cancer care. As an organization whose mission is to improve cancer care globally, NCCN stands in solidarity with the Ukrainian people. As part of that support, NCCN is providing free, Ukrainian-language cancer treatment information guides at NCCN.org/Ukraine.
“Our heart goes out to the people of Ukraine during this unjust invasion and humanitarian crisis,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “War not only threatens people's immediate safety, it also makes it much harder to provide necessary health care, including essential cancer care. We hope these Ukrainian-language treatment guides can offer some help to patients, their caregivers, and their providers during this difficult time.”
The NCCN resources include 14 newly-translated NCCN Guidelines for Patients® featuring patient-friendly, evidence-based, expert information on the following 8 topics in cancer care:
Breast Cancer (ductal carcinoma in situ/DCIS, invasive, and metastatic)
Head & Neck Cancers (nasopharyngeal, oral, and oropharyngeal)
Lung Cancer (early and metastatic)
Lymphomas (diffuse large B-cell)
Prostate Cancer (early and advanced)
The English-language versions of these patient guidelines are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)—the recognized standard for clinical direction and policy in cancer care and the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The patient versions are presented in an easy-to-read format via funding from the NCCN Foundation®, to help patients better understand their cancer care, especially when crossing geographic borders and receiving care in different settings.
“As hard as it is to endure an invasion, it can be even harder for people with cancer who have additional, urgent medical concerns,” said Nelya Melnitchouk, MD, Global Medical Knowledge Alliance (GMKA). “This Ukrainian-language information can help people with cancer and their health care providers understand where they are in their treatment journey and how to adapt their next steps in changing circumstances.”
“NCCN joins numerous organizations around the world that are answering the call to support Ukrainian cancer patients, their doctors, and their families,” said Mike Morrissey, Chief Executive, European Cancer Organisation (ECO). “We've gathered translated resources from many different medical and patient organizations in one place at onco-help.org, so the people who need this information can access it quickly and easily.”
NCCN's resource site builds on longstanding work and ongoing partnerships worldwide to also provide adapted and stratified versions of cancer guidelines that can help health care providers identify treatment options to provide the best possible outcomes in resource-constrained or conflict settings, among other unique regional concerns.
NCCN pledges to continue supporting the people of Ukraine by continuously updating the information at NCCN.org/Ukraine and on the NCCN apps. More resources are coming soon.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other initiatives. Follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg and Twitter @NCCN.
About the NCCN Foundation
The NCCN Foundation® was founded by the National Comprehensive Cancer Network® (NCCN®) to empower people with cancer and advance oncology innovation. The NCCN Foundation empowers people with cancer and their caregivers by delivering unbiased expert guidance from the world's leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. The NCCN Foundation is also committed to advancing cancer treatment by funding the nation's promising young investigators at the forefront of cancer research. For more information about the NCCN Foundation, visit NCCN.org/foundation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-cancer-information-resources-for-people-of-ukraine-from-nccn-301525092.html
SOURCE National Comprehensive Cancer Network
What if you could buy a Peloton with pre-tax dollars? All of those may likely qualify as purchases you could make through a Flexible Spending Account (FSA) or Health Savings Account (HSA). Both types of accounts allow people to contribute pre-tax dollars that they can spend on medical expenses, and in some cases, the funds in these accounts can grow through investments while they sit unused.
The trials that Nektar stopped included those involving a combination of its drug bempegaldesleukin with Bristol Myers Squibb Co's cancer drug Opdivo as well Merck & Co Inc's cancer drug Keytruda. Nektar and Bristol Myers were testing the combination therapy through an agreement signed in 2020, while the one with Keytruda involved a partnership entered with privately owned SFJ Pharmaceuticals last year.
Retirement planning is part savings, part guessing game. While many of your day-to-day expenses will remain the same, there are big-ticket categories that can take a large bite out of your savings. The average 65-year-old retired couple will need about $300,000 in after-tax savings to handle health care costs in retirement, according to a 2021 report from Fidelity.
Biotech stocks have put plenty of investors on the road to riches in recent years. Or we can refer to a smaller player like Novavax, which soared 2,700% in one year on optimism about its coronavirus vaccine program. Investors already know Moderna (NASDAQ: MRNA) for its blockbuster coronavirus vaccine, and that's why it might be overlooked right now.
There are clear paths for all of these companies to deliver huge returns to shareholders this decade.
The pharmaceutical industry has always been a land of new opportunities for growth investors, and with technological developments paving the way for groundbreaking discoveries, it would be fair to say that the outlook for this industry has never been any better.
Protagonist says the FDA plans to revoke its breakthrough designation for a blood cancer drug, and PTGX stock collapsed Thursday.
A surge of COVID-19 cases in New York State that is making it once again an epicenter of the U.S. pandemic is due to two new versions of the omicron variant, that appear even more infectious than the BA.2 subvariant that has become dominant in the U.S.
The Centers for Disease Control and Prevention has issued a warning of a rare, but potentially deadly disease in Florida.
The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the FDA has accepted for review. The FDA has provided a new target action date of July 13, 2022, and
The company leased the facility three years ago, handling construction through the Covid-19 pandemic and facing a clinical hold on its lead program late last year.
‘Had I known that anyone at the hospital had concerns about their ability to do that surgery, there is no chance I would have done it’
Anyone who lives with a chronic health condition likely has a daily medication routine. Fortunately, there are products that can alleviate symptoms, help avoid major health emergencies, and make it possible to go about a relatively normal life. But now, the Food&Drug Administration (FDA) has issued a warning for one daily medication you may want to know about. Read on to see which product is being pulled due to a potential health hazard.RELATED: These Common Heartburn and Pain Meds Were Just Rec
Memory lapsing? Becoming part of a clinical trial may be only a few clicks away.
Over the last few years, the new hotness was — you guessed it — coronavirus vaccines. Investing in vaccine stocks is no longer the speculator's ticket to riches, and as a group, the stocks might be headed for a decline. The first reason the reign of vaccine stocks may be ending is that coronavirus vaccines aren't expected to rake in as much cash compared to medicines from other segments as the pandemic eases over the next few years.
Republican Sen. Chuck Grassley, of Iowa, said this week that Republicans will not try to repeal the Affordable Care Act if they retake the Senate in November's midterm elections, the latest signal that the GOP is abandoning its long-running effort to scrap the health-care law also known as Obamacare. Grassley, 88, was among the most vocal opponents of the law when it was being debated by Congress more than a decade ago. Back then, some Republicans had falsely claimed that a provision in the ACA
I'm so here for all of this advice.View Entire Post ›
Never worked out before? Here's how to start getting fit now.
Regeneron Pharmaceuticals Inc. said Thursday that the Food and Drug Administration extended the review time by three months on whether to fully approve Regen-Cov as a treatment for non-hospitalized COVID-19 patients and as a prophylactic. Regeneron said the extension has to do with using Regen-Cov to prevent COVID-19 infections. Regen-Cov, which is a monoclonal antibody, was authorized as a COVID-19 treatment in November 2020; however, the therapy is not in use anywhere in the U.S. at this time
Britain's GlaxoSmithKline sought to bolster its cancer business on Wednesday by agreeing a $1.9 billion deal to buy U.S. drug developer Sierra Oncology, the latest move to fend off pressure from activist shareholder Elliott. GSK has been facing mounting calls to shore up its drug pipeline since Elliott built up a significant stake in the company last year. Shareholders in Sierra, a cancer drug developer, will receive $55 per share of common stock in cash, which is a 39% premium to the company's closing price on Tuesday.